As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.The news took the healthcare sector by storm, and the merger would position AstraZeneca as the world’s…
U.S. equities opened August with a broad-based relief rally Monday as crude oil tumbled and Treasury yields retreated from 18-month highs, after President Donald Trump called off a planned military strike on Iran over the weekend and said negotiations would resume.West Texas Intermediate crude sank…
After the biotech sector's worst month in more than a year, a potential combination between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) is putting oncology stocks back in focus.The SPDR S&P Biotech ETF (XBI) fell 7% in July, marking its worst monthly performance since March 2025.Why Bristol My…
Q2 2026 saw robust 14% growth in the portfolio, driving a 5% revenue increase to $13B and prompting raised full-year guidance. Key products like ELIQUIS, REBLOZYL, and CAMZYOS posted strong gains, while pivotal pipeline readouts and regulatory milestones are expected by year-end.Based on Bristol-My…
Q2 2026 saw 5% revenue growth to $13B, with the growth portfolio up 14% and ELIQUIS up 21%. Full-year guidance for revenue and EPS was raised, supported by strong product performance and a robust pipeline with multiple pivotal readouts and regulatory milestones ahead.Based on Bristol-Myers Squibb C…
Biopharmaceutical company Bristol Myers Squibb NYSE:BMY reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on year to $12.97 billion. The company’s full-year revenue guidance of $49.5 billion at the midpoint came in 4.3% above analysts’ estimates. Its no…
Q2 2026 revenues rose to $13.0B, driven by a 15% YoY increase in the Growth Portfolio and strong product-level performance across oncology, hematology, cardiovascular, immunology, and neuroscience. FY 2026 revenue and EPS guidance were raised, reflecting robust first-half results.Original document…
Biopharmaceutical company Bristol Myers Squibb NYSE:BMYwill be reporting results this Thursday before market open. Here’s what to look for.Bristol-Myers Squibb beat analysts’ revenue expectations last quarter, reporting revenues of $11.49 billion, up 2.5% year on year. It was a satisfactory quarter…
Bristol-Myers Squibb (NYSE:BMY) is racing AI-accelerated drug R&D — citing 20–30% faster candidate readiness and a new NVIDIA DGX SuperPOD — while advancing iberdomide toward an Aug. 17 FDA decision that could create the first approved CELMoD, pushing late-stage bispecific tumor programs and stirri…
Bristol Myers Squibb (NYSE: BMY, “BMS”), a global biopharmaceutical leader, today announced it will expand its compute infrastructure to deploy an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, giving BMS the most powerful and energy-efficient single-owned NVIDIA infrastructure in life scie…
Traders flagged Bristol-Myers Squibb (BMY) as a potential bidder for Sellas Life Sciences ahead of Sellas’s Regal AML readout; BMY has made no bid or official comment.Bristol-Myers
Shares of Sellas Life Sciences (SLS) jumped 3% overnight late Monday as retail traders bet that the final acute myeloid leukemia (AML) readout could turn this week’s Fox appearance into a launchpad for Big Pharma interest.SLS stock surged 12% on Friday to close at $13.19, capping a 3% weekly gain.S…
